A proliferation-inducing ligand (APRIL)-based CAR against BCMA and TACI inhibits the development of multiple myeloma [43], and B-cell-activating factor (BAFF) ligand-based CAR against BAFF-R, BCMA, and TACI inhibits the progression of B-cell tumors [36] by reducing antigen escape. This evidence concerns the gene TNFRSF13B and plasma cell myeloma.